Glucagon‐Like Peptide‐1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients With Systemic Lupus Erythematosus and Lupus Nephritis
We found lower risks of adverse CV and kidney outcomes and mortality with GLP-1RA use compared with DPP4i use among patients with lupus and T2D.
Authors
- April Jorge (ORCID: https://orcid.org/0000-0001-6935-880X)
- Aakash V. Patel (ORCID: https://orcid.org/0000-0002-4253-0822)
- Lingxiao Zhang (ORCID: https://orcid.org/0000-0002-7066-6065)
- Baijun Zhou
- Hyon K. Choi (ORCID: https://orcid.org/0000-0002-2862-0442)
Institutions
- Harvard University (US)
- Massachusetts General Hospital (US)
Publication Details
- Journal
- Arthritis & Rheumatology
- Published
- 2025-09-25
- DOI
- https://doi.org/10.1002/art.43403
- Citations
- 1
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 1.67